Fala, L. (2016). Entresto (Sacubitril/Valsartan): First-in-Class Angiotensin Receptor Neprilysin Inhibitor FDA Approved for Heart Failure. Am Health Drug Benefits.
Chicago Style aipamenaFala, Loretta. "Entresto (Sacubitril/Valsartan): First-in-Class Angiotensin Receptor Neprilysin Inhibitor FDA Approved for Heart Failure." Am Health Drug Benefits 2016.
MLA aipamenaFala, Loretta. "Entresto (Sacubitril/Valsartan): First-in-Class Angiotensin Receptor Neprilysin Inhibitor FDA Approved for Heart Failure." Am Health Drug Benefits 2016.
Kontuz: berrikusi erreferentzia hauek erabili aurretik.